Impact Factor
2.72
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
1.38
260 total citations
h5-index
17
h5 depth signal
Cited share
54.8%
108 of 197
Total citations
260
Citation footprint
Metric signal
1.26
External metric anchor
Self-citation
12.7%
33 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
597
China
94
United Kingdom
50
Japan
37
Germany
23
Citing Fields of Research
Statistical Methods
815
Medical Ethics
125
Clinical Laboratory Science
58
AI & Machine Learning
56
Oncology
48
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
2,607
Articles tracked across the journal lifetime
Indexed publication set
197
108 cited publications
Last 12 months
107
8.9 publications/month
Open access share
10.3%
11 OA publications in the last year
Leading citing country
United States
597 citing publications
Leading citing field
Statistical Methods
815 citing publications
Latest tracked publication
15 October 2026
10 recent records available
Coverage & Indexing History
v1n1, 1991-
v1n1, 1991-
Active Coverage
Research Focus & Classification
Indexed Subjects
Statistical Methods
Broad Categories
Pharmacology
Statistics as Topic
Statistical Methods
MeSH Descriptors
Biometry
Biopharmaceutics
Pharmacokinetics
Statistics as Topic
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1080/10543406.2026.2741423
Open DOI
Adaptation of Bayesian decision analysis for clinical trial design to binary outcomes: illustration for Ebola virus disease treatment
1. Designing a clinical trial during an outbreak of an emerging infectious disease is a major challenge. Viral hemorrhagic fevers (VHFs), including Ebola virus disease, are a group of febrile disea...
02
DOI 10.1080/10543406.2026.2741430
Open DOI
Estimands for combination therapy oncology trials with competing risks and their integration with Project SignifiCanT
1. The development of combination therapies in oncology has expanded rapidly as advances in immunotherapy, targeted agents, and biomarker-driven strategies have revealed opportunities for synergist...
03
DOI 10.1080/10543406.2026.2744763
Open DOI
Borrowing-dependent estimands in external-control trials: Identification, efficiency, and sensitivity in survival analysis
04
DOI 10.1080/10543406.2026.2741424
Open DOI
Comparison of multiple testing procedures for clinical trials with two doses and multiple ranked endpoints
05
DOI 10.1080/10543406.2026.2741428
Open DOI
A comparative evaluation of Bayesian model-assisted two-stage designs for Phase I/II clinical trials
06
DOI 10.1080/10543406.2026.2741426
Open DOI
The power prior for zero-inflated count models: Analysis based on episodes of urinary incontinence
07
DOI 10.1080/10543406.2026.2726747
Open DOI
The bivariate defective Marshall-Olkin Weibull distribution based on Clayton Copula and its application to medical survival data
08
DOI 10.1080/10543406.2026.2731184
Open DOI
Accounting for long-term survival: a smoothed piecewise model for event time projection in cellular immunotherapy trials
1. The advent of cancer immunotherapy, particularly cell therapy, has profoundly transformed the landscape of cancer treatment. This transformation necessitates the incorporation of specialized sur...
09
DOI 10.1080/10543406.2026.2729800
Open DOI
Model generalizability considerations in development and evaluation of SaMD
10
DOI 10.1080/10543406.2026.2728047
Open DOI
Trial designs for assessing induction, maintenance and other treatment effects on a continuous endpoint
Bibliographical & Catalog Notes
Title from cover.
Also issued online.
Vol. 4, no. 3 (1994)19950516 Notice published Printed on acid-free paper